Phase 3 trial evaluating efficacy and safety of odronextamab plus CHOP vs rituximab plus CHOP in previously untreated diffuse large B-cell lymphoma (DLBCL; OLYMPIA-3).

Basit Öğe Kaydı
dc.contributor.authorMatasar, Matthew
dc.contributor.authorTurgut, Burhan
dc.contributor.authorTessoulin, Benoit
dc.contributor.authorGuidez, Stephanie
dc.contributor.authorAltuntas, Fevzi
dc.contributor.authorIqbal, Nazia
dc.contributor.authorNamuduri, Manjusha
dc.date.accessioned2024-10-29T17:58:16Z
dc.date.available2024-10-29T17:58:16Z
dc.date.issued2024
dc.departmentTekirdağ Namık Kemal Üniversitesi
dc.descriptionSpecial Clinical Science Symposia -- MAY 29-29, 2024 -- ELECTR NETWORK
dc.description.abstract[Abstract Not Available]
dc.description.sponsorshipRegeneron Pharmaceuticals, Inc.
dc.description.sponsorshipRegeneron Pharmaceuticals, Inc.
dc.identifier.issn0732-183X
dc.identifier.issn1527-7755
dc.identifier.issue16en_US
dc.identifier.urihttps://hdl.handle.net/20.500.11776/14165
dc.identifier.volume42
dc.identifier.wosWOS:001275557406337
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.language.isoen
dc.publisherLippincott Williams & Wilkins
dc.relation.ispartofJournal of Clinical Oncology
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.titlePhase 3 trial evaluating efficacy and safety of odronextamab plus CHOP vs rituximab plus CHOP in previously untreated diffuse large B-cell lymphoma (DLBCL; OLYMPIA-3).
dc.typeConference Object

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu